Efficient Expression of HIV in Immunocompetent Mouse Brain Reveals a Novel Nonneurotoxic Viral Function in Hippocampal Synaptodendritic Injury and Memory Impairment

Jennifer Kelschenbach, Hongxia He, Boe-Hyun Kim, Alejandra Borjabad, Chao-Jiang Gu, Wei Chao, Meilan Do, Leroy R. Sharer, Hong Zhang, Ottavio Arancio, Mary Jane Potash, David J. Volsky

ABSTRACT HIV causes neurodegeneration and dementia in AIDS patients, but its function in milder cognitive impairments in virologically suppressed patients on antiretroviral therapy is unknown. Such patients are immunocompetent, have low peripheral and brain HIV burdens, and show minimal brain neuropathology. Using the model of HIV-related memory impairment in EcoHIV-infected conventional mice, we investigated the neurobiological and cognitive consequences of efficient EcoHIV expression in the mouse brain after intracerebral infection. HIV integrated and persisted in an expressed state in brain tissue, was detectable in brain monocytic cells, and caused neuroinflammatory responses and lasting spatial, working, and associative memory impairment. Systemic antiretroviral treatment prevented direct brain infection and memory dysfunction indicating the requirement for HIV expression in the brain for disease. Similarly inoculated murine leukemia virus used as a control replicated in mouse brain but not in monocytic cells and was cognitively benign, linking the disease to HIV-specific functions. Memory impairment correlated in real time with hippocampal dysfunction shown by defective long-term potentiation in hippocampal slices ex vivo and with diffuse synaptodendritic injury in the hippocampus reflected in significant reduction in microtubule-associated protein 2 and synapsin II staining. In contrast, there was no evidence of overt neuronal loss in this region as determined by neuron-specific nuclear protein quantification, TUNEL assay, and histological observations. Our results reveal a novel capacity of HIV to induce neuronal dysfunction and memory impairment independent of neurotoxicity, distinct from the neurotoxicity of HIV infection in dementia.

IMPORTANCE HIV neuropathogenesis has been attributed in large measure to neurotoxicity of viral proteins and inflammatory factors produced by infected monocytic cells in the brain. We show here that HIV expression in mouse brain causes lasting memory impairment by a mechanism involving injury to hippocampal synaptodendritic arbors and neuronal function but not overt neuronal loss in the region. Our results mirror the observation of minimal neurodegeneration in cognitively impaired HIV patients on antiretroviral therapy and demonstrate that HIV is nonneurotoxic in certain brain abnormalities that it causes. If neurons comprising the cognition-related networks survive HIV insult, at least for some time, there is a window of opportunity for disease treatment.

KEYWORDS EcoHIV, HAND, mouse models, radial arm water maze, synaptodendritic injury
HIV infection causes brain abnormalities known as HIV-associated neurocognitive disorders (HAND) that include HIV-associated dementia (HAD) and two non-HAD neurocognitive impairments (NCI), asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND) (1). Individuals with stable virologic suppression by antiretroviral therapy (ART) rarely progress to HAD, but about 50% of them will develop NCI (2–4). ANI, diagnosed only in neuropsychological tests, is the largest NCI category in patients on ART, and the number of cases is also increasing (5, 6). ANI poses an increased risk of symptomatic disease (7, 8), and aging increases the severity of both disorders (3, 9, 10), indicating substantial long-term health consequences.

The frequency of NCI raises the question of how HIV causes this impairment. Studies in HAD patients and animal models of HIV encephalitis (HIVE) linked dementia to HIV replication, CD4+ T cell depletion/immunodeficiency, and neuroinflammatory and neurotoxic effects of HIV proteins produced by infected cells in the brain (reviewed in references 11 and 12). Although NCI was described in AIDS patients independent of dementia (13, 14), the failure of ART to prevent NCI (2, 3) suggests routes of HIV neuropathogenesis unlinked to virus burden and immunodeficiency and different from HAD/HIVE (15, 16). Further mechanistic differences are apparent in the limited neurodegeneration in NCI patients on ART (15, 17) and are reflected in the stable cognitive disease course in the majority of individuals on ART monitored for 3 to 4 years (3, 9, 10). Brain pathology studies on NCI revealed that NCI correlates better with cortical synaptodendritic simplification than with prominent neuronal loss (13, 18, 19). Neuronal dysfunction independent of neuronal loss is now considered the major pathobiological feature distinguishing NCI from HAD (6). Collectively, these findings suggest that HIV may act differently in causing NCI and HAD. Given that ART suppresses HIV replication, part of this difference could be quantitative, but the demonstration of mild NCI in AIDS patients with high virus burdens (13, 18) speaks against it. In addition, HIV RNA can be detected in brain tissues and CSF from NCI patients with undetectable HIV in plasma (3, 20), suggesting ongoing virus expression in the central nervous system. Alternatively, HIV could cause nonnecrotic neuronal dysfunction or neurodegeneration depending on host conditions, for example being related to aging (21).

We have employed chimeric HIV, EcoHIV (22), to investigate NCI in conventional immunocompetent mice. EcoHIV-infected mice mount protective antiviral immune responses and have low virus burdens and normal brain histopathology, yet they manifest learning and memory dysfunctions (named murine NCI) that resemble human NCI (23–25). As shown recently, murine NCI correlates with synaptodendritic injury in the hippocampus and both the injury and NCI can be reversed by intranasal insulin treatment, suggesting that some injured neurons remain viable (26). Here, we used intracerebral (i.c.) virus delivery for efficient EcoHIV infection in immunocompetent mouse brain (24, 27) to directly evaluate the neurobiological and cognitive effects of HIV expression in the mouse brain.

## RESULTS

**EcoHIV but not MLV impairs memory in wild-type mice.** Animal lentivirus models of HIV brain disease generally reproduce HIVE in immunodeficient hosts with high virus brain burdens (28). To test the pathogenicity of brain-resident HIV in an immunocompetent host, wild-type 129X1 mice were inoculated intracerebrally with EcoHIV or murine leukemia virus (MLV) (24, 27) and, starting 10 days after infection, the animals were tested in a RAWM for visuospatial learning and memory (Fig. 1A and B). MLV, the donor of viral envelope in EcoHIV (22), was used both as an unrelated retrovirus control and to control for effects of MLV envelope in EcoHIV. Because the location of the submerged platform is altered randomly on each day of the test, the animals must use working memory to learn the platform location (29–31). Saline- and MLV-inoculated mice learned and retained acquired information equally well, but EcoHIV-infected mice were significantly impaired at all testing stages (significant main effect of trial $F_{(5,359)} = 9.152, P < 0.001$ and infection $F_{(2,359)} = 40.041, P < 0.001$) (Fig. 1A). The infected and control mice were equally adept in finding the visible platform (Fig. 1B), suggesting that
FIG 1 EcoHIV and MLV efficiently replicate in mouse brain but only EcoHIV causes learning and memory impairments. (A and B) The RAWM test of mice inoculated intracranially with EcoHIV (closed circles), MLV (gray circles), or saline (open circles). Testing was conducted over 12 days starting 10 days after infection (n = 8 per group). (A) Mean number of errors ± the standard errors of the mean (SEM) made on the last 3 days of RAWM testing with the hidden platform. T1 to T4 denote acquisition trials, and RT denotes the retention trial performed after a 30-min delay. F(2,71) = 8.951, P < 0.001/T2, F(2,71) = 14.171, P < 0.001/T3, F(2,71) = 11.444, P < 0.001/T4, F(2,71) = 14.671, P < 0.001/R; (***, P < 0.001). (B) Mean latencies ± the SEM in finding the visible platform on trial 4 on days 1 and 2 of visible platform testing. (C and D) The auditory-cued fear conditioning test 2 weeks after intracranial inoculation with EcoHIV or saline (n = 8 per group). The figure shows the mean percentages of time spent freezing ± the SEM during paired sound-shock conditioning sessions on day 1 of the test (C) and sound (cued) response sessions in a new context on day 2 of the test (D). (E) Schematic representation of the shared MLV gp80 env gene in EcoNDK and MLV. (F and G) Quantification of EcoHIV (black bars) and MLV (gray bars) showing DNA or RNA burdens, respectively, in the brain tissues of mice after completion of the RAWM test shown in panels A and B. The env DNA or RNA region was amplified by QPCR or RT-QPCR, respectively; results are mean copies ± the SEM. (H to J) In a parallel experiment, three mice each were infected intracranially with EcoHIV, and 2 weeks later the brain tissues were tested by QPCR for HIV 2LTR and integrated DNA (H), by RT-QPCR for HIV Gag and Tat RNA (I), and by Southern blot hybridization for Nef transcript (J). The results in panels H and I are mean copies ± the SEM; β-actin RNA amplified in parallel served as a loading control in panel J. (K) Detection and cellular localization of viral proteins in mouse brain sections 2 weeks after intracranial infection of three to four mice each with EcoHIV (left panels), EcoHIV-GFP (middle panels), or MLV-GFP (right panels). Representative images from five to seven sections in each mouse are shown. (Left panel) Detection of HIV p24 by immunohistochemical (IHC) staining evaluated by light microscopy. Note the p24-positive cells near a perivascular lesion (top) and in the brain parenchyma (bottom). Magnification, ×25. (Middle panel) Localization of HIV-encoded GFP in monocytoid cells by costaining for macrophage marker Iba-1 (red), GFP (green), and nuclear marker DAPI (blue) and evaluation by fluorescence microscopy. Individual channels and a merge image are shown. (Right panel) Detection of MLV-encoded GFP by costaining for GFP (green), nuclear marker DAPI (blue), and either astrocyte marker GFAP (red, upper image) or macrophage marker Iba-1 (red, lower image) and evaluation by fluorescence microscopy. Representative merged images are shown. Note the absence of colocalization of GFP with either GFAP or Iba-1.
neither EcoHIV nor MLV affected the visual, motor, or motivational circuits in the brain. To examine another cognitive domain, infected mice were tested in a fear conditioning (FC) test (Fig. 1C and D) for assessment of amygdala-dependent fear memory (32, 33). Control and infected mice learned equally well to associate electric shock and sound during the conditioning session on day 1 (Fig. 1C), but infected/conditioned animals spent less time “freezing” (motionless) than control/conditioned mice when exposed the next day to a sound cue alone (Fig. 1D; $P = 0.026$), suggesting the impairment of sound-cued associative memory in these mice. Thus, EcoHIV infection of mouse brain impairs hippocampus- and amygdala-dependent memory circuits, while MLV was cognitively benign.

**EcoHIV and MLV replicate well in mouse brain, but only EcoHIV infects macrophages/microglia.** We next inquired whether the difference between EcoHIV and MLV in cognitive disease outcomes could be explained by their infection phenotypes in mouse brain (Fig. 1E to K). Quantitative PCR (QPCR) amplification of a common region in the gp80 gene depicted in Fig. 1E allows equal detection of both viral genomes. Both EcoHIV- and MLV-infected mice had high env DNA (Fig. 1F) and RNA burdens (Fig. 1G) at the completion of the behavioral experiment shown in Fig. 1A and B, demonstrating efficient infection by either virus. However, only EcoHIV-infected mice carried HIV products 2LTR DNA and integrated DNA (Fig. 1H), Gag RNA and Tat RNA (Fig. 1I), and nef RNA (Fig. 1J), allowing a distinction between EcoHIV and MLV detection. Specific detection of 2LTR and integrated DNA and tat and nef transcripts provides a quantitative measure of HIV infection and expression de novo in mouse brain because these HIV products are absent from the viral inoculum. Finally, to visualize HIV and MLV products in specific cells in mouse brain in vivo, brain sections from mice infected with EcoHIV-GFP and MLV-GFP were stained for HIV p24, virus-expressed green fluorescent protein (GFP), and cell-lineage specific markers (Fig. 1K). Consistent with previous observations (27), EcoHIV-infected mice had clearly detectable HIV p24-positive cells in brain parenchyma near perivascular lesions typical of intracerebral HIV infection (Fig. 1K, left panel) and virus-expressed GFP localized to Iba-1-positive macrophages/microglia (Fig. 1K, EcoHIV-GFP panel, merge). In contrast, MLV-GFP localized to irregularly shaped cells near the lateral ventricles, and these cells did not express either astrocytic or monocyteid cell markers (Fig. 1K, MLV-GFP panel, only merged images for either GFP/GFAP or GFP/Iba-1 are shown). Thus, both EcoHIV and MLV replicate well in mouse brain, but EcoHIV infects macrophages/microglia and causes cognitive impairment, and MLV does not.

**EcoHIV, but not MLV, induces microglial activation and inflammatory responses in the basal ganglia region but not apoptosis.** We next examined brain tissues from EcoHIV- and MLV-infected mice for evidence of neuroinflammation, which generally accompanies HIV-mediated brain disease (34). The basal ganglia region, the site of viral inoculation, was tested for morphology and microglial activation on paraffin-embedded brain sections, and RNA extracts from this region were tested for cellular inflammatory and interferon-related gene expression (Fig. 2A to C). Brain sections from EcoHIV-infected but not MLV-infected mice showed perivascular lesions defined as infiltrates of mononuclear cells ($P < 0.0001$/saline versus EcoHIV, $P < 0.0001$/MLV versus EcoHIV) and exhibited marked macrophage/microglial cell activation ($P < 0.0001$/saline versus EcoHIV, $P < 0.0001$/MLV versus EcoHIV-percent stained) and increased density of activated cells ($P = 0.007$/saline versus EcoHIV, $P = 0.006$/MLV versus EcoHIV-cells/field) (Fig. 2A and B). Consistent with these results, only brains from EcoHIV- but not MLV-infected mice showed significant upregulation of all 12 inflammation-related genes selected for this study (Fig. 2C). MLV induced only one of the genes tested, IFN Regulatory Factor-7 (IRF7), confirming the difference in brain pathology profiles between EcoHIV and MLV. The results also exclude the MLV envelope protein in EcoHIV as a potential cause of brain pathologies and NCI seen in EcoHIV infection. Finally, because HIV replication in the brain and neuroinflammation usually correlate with cellular apoptosis (35), we also tested duplicate brain sections from EcoHIV- and MLV-infected mice analyzed in Fig. 2A and B for presence of apoptotic cells
FIG 2  EcoHIV, but not MLV, infection results in pathological changes in the brain and induction of selected host inflammatory and immune activation genes in brain tissue. Mice were inoculated intracranially with EcoHIV, MLV, or saline (three to four mice/group); 2 weeks later, the brains were fixed in paraformaldehyde (PFA), embedded in paraffin, sectioned, and stained or processed for TUNEL assay. The photomicrographs show representative fields from the right basal ganglia region in the vicinity of the injection site in each experimental system. (A) H&E staining depicting inflammatory cell infiltration in EcoHIV-infected mice and no apparent pathology in either MLV or PBS controls. (B) IHC staining for macrophage/microglia marker Iba-1 indicating intense microglial activation in EcoHIV-inoculated mice but minimal activation in MLV infection and saline control. (C) In a separate experiment from that shown in Fig. 1, mice (n = 5 per group) were intracranially inoculated with EcoHIV (black bar), MLV (gray bar), or saline (open bar); 2 weeks later, the mice were sacrificed, and total cellular RNAs from brain tissues were compared by RT-QPCR for the expression of genes known to be involved in HIV-1 neuropathogenesis in infected people. The results are shown as the mean fold change ± the SEM versus saline controls set as 1.0. (D) TUNEL staining depicting no significant cell death in any experimental groups. Scale bars are indicated in the bottom left corner of images, and quantifications are shown to the right of each panel (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
in the basal ganglia region by TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling) assay (Fig. 2D). No cell death was detected in MLV-infected brains (Fig. 2D). Surprisingly, however, brain tissues from EcoHIV-infected mice were also TUNEL assay negative (Fig. 2D), despite significant activation of inflammation related genes in the brain (Fig. 2C). Together, the results show that the intracerebral expression of EcoHIV but not MLV induces cognitive impairment in mice, that the impairment does not involve cell death in the regions tested, and that the difference in cognitive disease outcomes of the two viruses is likely due to expression of HIV-specific gene products and not the envelope gene shared by both viruses.

**EcoHIV replication in mouse brain is required for induction of cognitive impairment.** To determine role of HIV replication in mouse brain in NCI induction, mice were subjected before and during intracerebral EcoHIV infection to daily gavage of a cocktail of three antiretroviral drugs (ARV) used in clinical practice (36). ARV prophylaxis clearly mitigated impairment of memory acquisition during the learning phase and completely prevented impairment in the retention phase (RT) in the RAWM test (significant main effect of trial $F_{(4,419)} = 7.440 \ [P < 0.001]$ and treatment $F_{(2,419)} = 8.075 \ [P < 0.001]$) (Fig. 3A). ARV treatment alone had no effect on mouse cognition in this test, and all animal groups tested were equally adept in finding the visible platform (Fig. 3A and B). ARV prophylaxis also largely but not completely prevented EcoHIV infection in the brain, as indicated by significant reduction in the HIV 2LTR ($P = 0.0023$).
and integrated DNA ($P = 0.0094$) brain burdens compared to untreated mice (Fig. 3C). These results indicate a link between the extent of HIV infection in mouse brain and the induction of NCI in infected animals.

**Murine HIV-NCI persists despite host seroconversion and reduction in virus expression and neuroinflammation.** Mild HIV-NCI is a lifelong condition in infected people with stable control of HIV replication (6). To test the persistence of mouse HIV-NCI, mice were infected by intracerebral injection as described in Fig. 1, and groups were tested for NCI 10 or 60 days after virus inoculation (Fig. 4). As expected, the animals tested 10 days after infection manifested significant impairment of memory acquisition and recall in RAWM ($P = 0.0013/T2$, $P < 0.0001/T3$, $P < 0.0001/T4$, and $P = 0.0006/RT$) (Fig. 4A), reproducing the findings of Fig. 1 and 3. The group of infected mice tested 2 months after infection also showed significant impairment ($P = 0.0486/T2$, $P = 0.0036/T3$, $P = 0.0306/T4$, and $P = 0.0064/RT$), suggesting that HIV causes lasting cognitive damage in mice (Fig. 4B). HIV DNA and RNA burdens in the brain declined between 10 and 60 days after infection, but transcriptionally active HIV was still detectable at the later time point (compare Fig. 4C to Fig. 1). Low levels of HIV DNA and RNA were also detected in the spleen cells of intracerebrally infected animals (Fig. 4D) and anti-HIV Gag antibodies were found in serum 6 weeks after infection (Fig. 4E), indicating that HIV can disseminate from the brain to peripheral tissues and induce adaptive antiviral immune responses. Finally, because induction of murine HIV-NCI by HIV was accompanied by marked induction of genes controlling inflammatory and innate immune responses (Fig. 2), we tested whether these responses persisted as observed for the cognitive disease. Mice were infected intracerebrally, and groups were tested for changes in expression of selected inflammatory and interferon-related genes 15, 30, or 60 days after infection (Fig. 4F). The expression of genes encoding major inflammatory determinants tested including cytokine interleukin-6, complement component C3, and chemokine CCL2 declined from the high levels 15 days after infection to control values 60 days after infection (Fig. 4F). Similar declines were observed for transcripts of several type I interferon-related genes tested, including IRF1, IRF7, and IF10. The expression of the transcription factor STAT1 also declined over time, but it remained significantly elevated above control 2 months after infection. In contrast, the expression of syntaxin-6 (STX6), a regulator of intracellular membrane trafficking (37), increased 30 days after HIV infection and remained above control levels 30 days later (Fig. 4F). These results suggest that HIV infection of immunocompetent mouse brain causes cognitive disease that remains stable despite normalization of expression of multiple inflammatory genes tested in the brain.

**Murine HIV-NCI correlates with hippocampal synaptodendritic injury and neuronal dysfunction but not neuronal apoptosis in the region.** We next examined neuronal function and integrity in the hippocampus area, the site involved in visuospatial memory deficits seen in HIV-positive individuals on ART (38, 39) and in peripherally EcoHIV-infected mice (23, 26). For functional studies, intracerebrally EcoHIV-infected mice were first tested for manifestation of learning/memory impairment in RAWM 10 days after infection (Fig. 5A); subsequently, pairs of infected and saline-inoculated controls were serially sacrificed over the following 2 weeks for LTP determination in the CA1 area of acute hippocampal slices (Fig. 5B to D). Consistent with the results shown in Fig. 1, 2, and 4, infected mice suffered significant memory impairment compared to saline controls ($P = 0.0207/T3$, $P = 0.0171/T4$, and $P = 0.001/RT$) (Fig. 5A). The impaired mice also showed significantly reduced LTP in the CA1 area of hippocampal slices compared to controls; both the early and late phases of LTP were affected ($P = 0.0015$/hour 1 and $P = 0.0086$/hour 2) (Fig. 5B and C). In contrast, baseline synaptic transmission and input-output curves were similar in infected and control mice (Fig. 5D), suggesting that HIV brain infection in this model impacts long-term synaptic plasticity and not basal synaptic transmission.

In parallel, we examined the extent of physical neuronal injury in the hippocampus 2 weeks after intracerebral infection of mice, the time of initial HIV-NCI manifestation in these animals. Several evaluations were performed. First, we used immunofluorescence
staining and confocal microscopy to quantify the expression of the dendritic/axonal marker protein MAP2 (40, 41) and neuronal nuclear protein NeuN in the hippocampi of infected and control animals (Fig. 6A to C). Compared to uninfected mice, EcoHIV-infected animals showed significant decline of about 50% in the intensity of MAP2

FIG 4 EcoHIV infection in the brain and virus-induced NCI are maintained despite host seroconversion. In two separate experiments, mice (n = 10 to 12 mice per group) were intracranially inoculated with EcoHIV or saline. (A and B) Mean numbers of errors ± the SEM made on the last 3 days of RAWM testing for EcoHIV (filled circles) and saline (open circles) inoculated mice 10 days (A) and 2 months (B) postinoculation, T1 to T4 denote acquisition trials, and RT denotes the retention trial performed after a 30-min delay. (C) HIV Gag DNA, Gag, and Vif RNA burdens tested by QPCR/RT-QPCR in brain tissues from EcoHIV-infected mice 2 months after infection, shown as mean copies ± the SEM. (D) HIV Gag DNA and Gag RNA burdens tested by QPCR/RT-QPCR in spleen cells from EcoHIV-infected and control mice 2 months after infection, shown as mean copies ± the SEM. (E) Titers of HIV Gag-specific serum IgG antibodies in mice inoculated intracranially with EcoHIV (closed circles) or saline (open circles) and tested 2 months after infection. Horizontal line indicates mean. **, P < 0.01. (F) In a separate experiment, mice (n = 3 per group) were intracranially inoculated with EcoHIV; at 15, 30, and 60 days postinfection, mice were sacrificed, and total cellular RNAs from brain tissues were compared by RT-QPCR expression of genes known to be involved in HIV-1 neuropathogenesis in infected people. The results are shown as the mean fold changes ± the SEM versus saline controls set as 1.0.
staining in hippocampal CA1 and CA3 regions \((P = 0.0102/CA1 \text{ and } P = 0.0337/CA3)\), while NeuN detection was unchanged, suggesting dendritic dearborization in the hippocampus. To determine whether reduction in MAP2 staining is accompanied by reduced detection of presynaptic termini, duplicate sections were costained with NeuN and mouse presynaptic marker Syn2 \((P = 1.02)\), and the fluorescence intensity was quantified \((P = 0.01)\). The Syn2 staining was visibly diminished in EcoHIV-infected mice compared to control mice (saline) throughout the hippocampus, as exemplified in representative merged images (NeuN, red; Syn2, green) from the CA3 area in Fig. 6D.

The decline in Syn2 marker detection in infected animals was significant compared to uninfected animals \((P = 0.0047)\), while NeuN detection was not significantly changed \((P = 0.0006)\). Both groups showed similar relationships \((P > 0.05)\).

**Fig 5** Infected mice with HIV-NCI have reduced LTP in the hippocampus. Mice were inoculated intracranially with EcoHIV or saline (10 animals per group); 10 days later, the animals were tested for NCI in RAWM and then returned to their cages. After a period of rest, pairs of infected and control mice were sacrificed, and hippocampal slices were prepared for electrophysiological measurements. (A) Mean number of errors \(\pm\) SEM made on the last 3 days of RAWM testing for EcoHIV (filled circles) and saline (open circles). T1 to T4 denote acquisition trials, and RT denotes the retention trial performed after a 30-min delay. *, \(P < 0.05\); **, \(P < 0.01\). (B) Summary graph of LTP in saline (open circles) and EcoHIV (filled circles) hippocampal slices. The average fEPSP slope is normalized to the baseline value \((\text{ANOVA, } P = 0.0006)\). (C) Quantification of the last 10 min of the first hour and the second hour of LTP recordings. **, \(P < 0.01\). (D) Summary graph of field input-output relationships for saline (open circles) and EcoHIV (filled circles) hippocampal slices. Both groups showed similar relationships \((P > 0.05)\).
EcoHIV-infected mice show loss of hippocampal dendrites and presynaptic terminals with preservation of neuronal cell bodies. In a separate experiment, mice (n = 3 per group) were intracranially inoculated with either saline or EcoHIV; at 14 days postinfection, (Continued on next page)
apoptosis (Fig. 7). Visual examination of H&E-stained sections suggested normal hippocampal neuronal morphology in infected mice compared to controls (Fig. 7A), while TUNEL assay results showed a minimal number of apoptotic nuclei in infected animals (Fig. 7B and C). Together, the results shown in Fig. 6 and 7 suggest that EcoHIV infection of mice causes a largely nonapoptotic synaptodendritic injury in the hippocampus that correlates with hippocampal neuronal dysfunction and memory impairment.

**DISCUSSION**

Our work links HIV expression in immunocompetent mouse brain to memory impairment and neuronal dysfunction in the absence of significant cell loss in the hippocampus, revealing a novel nonneurotoxic function of HIV in cognitive impairment. These findings advance understanding of the HIV role in neuropathogenesis and may inform design of interventions.

Intracerebral infection of conventional mice with EcoHIV allows efficient HIV expression in the brain accompanied by cell activation and inflammatory responses (24, 27). We now show that this infection causes cognitive abnormalities resembling murine NCI in peripherally infected mice (23, 26). Spatial memory dysfunction in the RAWM implies hippocampal injury (30), and a deficient working memory suggests the disruption of executive functions involved in sequential processing of information acquired during learning (29, 43, 44). The fear circuit impairment indicates respective injury to hippocampus and amygdala and possibly a faulty connectivity with prefrontal cortex (PFC) for memory consolidation and recall (32, 33). Together, the cognitive impairments in intracerebrally and intraperitoneally EcoHIV-infected mice resemble, respectively, the HAD-independent cognitive impairments observed initially in AIDS patients (13, 14) and currently (and overwhelmingly) in patients on HIV-suppressive ART (6, 45–47). As in these patients, the cognitive domains affected imply widespread viral injury to neuronal networks spanning the PFC to medial lateral lobe (46). Notably, control mobility tests in RAWM (Fig. 1B) indicated that infected mice lack the gross motor impediments of patients with HIV dementia (48, 49). The dopaminergic neuronal damage in EcoHIV-infected mice (50) could affect fine psychomotor abilities seen in NCI (1), but this possibility has not been tested. Further studies are needed to determine the full range of cognitive and motor abnormalities in this model.

Several observations in the present work link HIV expression in the brain to memory impairment, including prevention of HIV brain infection and NCI with systemic antiret-

---

**FIG 6 Legend (Continued)**

the mice were sacrificed and perfused with PFA, and frozen brain sections were prepared and double stained with NeuN and MAP2 or Syn2. (A and B) Representative 20× images from the CA3 and CA1 hippocampal regions, respectively, of control (saline) and EcoHIV-infected mice stained for NeuN (top panels), MAP2 (middle panels), and merge (bottom panels). White boxes indicate regions that were quantified, and signal quantification results normalized per image area are shown in panel C. * P < 0.05. (D) Representative merged images from the CA3 region stained with NeuN (red) and Syn2 (green). Original magnification, ×40. (E) Quantification of NeuN and Syn2 fluorescence. (F) Representative merged Z-stack images (each digitally reconstructed from 50 images) showing, at high resolution, MAP2 (green) and NeuN (red) staining of entorhinal cortex dorsal to CA1. Original magnification, ×65.
roviral prophylaxis; the persistence of brain infection along with cognitive disease, reminiscent of observations in HIV-suppressed NCI patients (20, 51); and the real-time correlation between NCI and expression of tat and nef transcripts that encode proteins implicated in HIV neuropathogenesis (52). While we did not attempt to detect Tat protein in the brain here, its production in EcoHIV-infected mice was reported previously (22). Notably, the intracerebrally inoculated MLV used as a control virus replicated well in mouse brain but did not cause NCI, confirming that HIV-specific functions were required for NCI induction in this model. Because MLV and EcoHIV share the gp80 envelope gene (22), this control also demonstrates that murine NCI cannot be attributed to MLV envelope in EcoHIV. The detection of HIV proteins in brain monocytic cells here and previously (27) suggests that these cells are the main targets for EcoHIV expression in this model, demonstrating commonality of murine NCI and HAND through the proposed central role of monocytic cells for HIV infection in the brain and neuropathogenesis (23, 53, 54). Conversely, the failure of MLV to induce NCI here could be attributed to its inability to infect and activate brain myeloid cells. A difference in EcoHIV and MLV tropism to monocytic cells was observed previously and found not to solely depend on the cellular display of CAT-1, the receptor for MLV and EcoHIV (23). Murine retrovirus tropism is conferred by both viral envelope and LTR (55), suggesting that LTR activity and host cell transcription factors contribute to EcoHIV tropism in mice. Finally, it should be noted that the spleen was not infected in intracerebrally inoculated mice when NCI was first detected, suggesting that infection confined to the brain was sufficient for initiating the cognitive disease development. Low levels of HIV were detected in the spleen 2 months after infection (Fig. 4), suggesting dissemination of virus from the brain and likely the source of antigen for the observed seroconversion of intracerebrally inoculated mice. This virus could also contribute to NCI, for example, by promoting chronic systemic inflammation (23, 56–58).

Considering that we intentionally maximized EcoHIV infection in mouse brain, observing both neuroinflammation and expression of HIV genes encoding HIV neurotoxins, it was surprising that we saw minimal neuronal loss in the basal ganglia region, the site of virus inoculation, and in hippocampus and entorhinal cortex, the sites required for the cognitive functions tested here. This is a different neuropathological outcome than in HIV and SIV encephalitis, where neuronal death prevails and is thought to result from combined effects of viral neurotoxins and neuroinflammation (28, 59–61). A recent study reported loss of dopaminergic but not nondopaminergic neurons in the substantia nigra and subventricle brains of EcoHIV-infected mice (50), suggesting that EcoHIV infection may reproduce some of the neuron type-specific neurotoxic functions of HIV (18). However, our results clearly associate HIV brain infection and spatial memory impairment in real-time with nonnecrotic hippocampal neuronal injury reflected in extensive dendritic dearborization and reduced synaptic density. LTP measurements in hippocampal slices ex vivo link this injury to hippocampal synaptic dysfunction. Synaptodendritic simplification was also observed in entorhinal cortex, suggesting diffuse nature of HIV-mediated neuronal injury and potential functional disruption of the major neuronal pathway for spatial navigation connecting between thalamus and PFC (62). Together, these results suggest that losses of synapses, dendritic integrity, and neuronal function in the hippocampus and not neuronal death are the primary neurobiological defects responsible for memory deficits in this model. We recently reached similar conclusions in studies in peripherally EcoHIV-infected mice by showing that memory impairment in these mice can be reversed with appropriate interventions (25, 26). In particular, the observation that intranasal insulin treatment rapidly restores hippocampal dendritic arbors and functional memory clearly indicates that neuronal cells required for spatial memory recording survive HIV insult in this model and can regain full functionality (26). Our conclusions are concordant with the view of mild cognitive impairment as “mainly a synaptodendritic disorder” that is largely independent of neuronal loss (18). Notably, this insight originated from analysis of brain tissues in AIDS patients with active HIV expression and neuroinflammation (13, 18), akin to the system described here. The extent of neurodegeneration in untreated
HIV-positive patients was recently shown to correlate directly with plasma HIV burdens and inversely with CD4$^+$ T cell levels (63). HIV-positive individuals on ART have normal CD4 levels and minimal neurodegeneration, regardless of whether they manifest NCI (15, 63, 64). However, their cognitive impairment still correlates best with a combined reduced display of dendritic and synaptic markers (19), similar to the findings here. To our knowledge, EcoHIV-infected mice with memory impairment are the only animal model of HIV infection that reproduces, at least regionally in the brain, the nonnecrotic structural-functional injury of neurons that may underlie NCI in individuals on ART.

Animal models can only approximate the processes involved in human disease (65). Further studies are needed to determine the basis of neuronal injury in the PFC and other anatomical sites involved in cognitive deficits in the EcoHIV model. However, our recent reports (23, 25, 26) and this one allow us to make two general points on HIV neuropathogenesis in the ART era. First, HIV expression in brain tissue is sufficient, and may be the only trigger required, for the induction of cognitive impairment. Because HIV enters the human brain early in infection (66, 67), and cognitive disease can develop even when ART is initiated within weeks of infection (68), new treatment paradigms will have to be developed to prevent the disease. Second, our data reveal a nonneurotoxic function of HIV in cognitive impairment distinct from HIV neurotoxicity in dementia. We propose that the ability to cause this injury is intrinsic to multifunctional HIV proteins such as Tat or Nef (52, 69), as exemplified by nonneurotoxic synaptic dysfunction and memory impairment in young inducible-Tat transgenic mice (70).

Nonnecrotic synaptodendritic damage is likely superseded during the extensive neuroinflammation in HIV by frank cell death caused by cellular neurotoxins and brain homeostasis breakdown, as well as injurious viral proteins (48, 53, 71). However, when virus control in the brain is provided by immune responses (27, 72) or effective ART, noncytopathic neuronal injury may prevail, at least temporarily, as indicated by stable NCI course in the majority of patients followed in longitudinal studies for 3 to 4 years (3, 9, 10). That neurons can survive HIV insult under some host conditions has important implications for control of the disease. If neurons are injured but viable, reversal of synaptodendritic injury and neuronal functionality is possible as shown after moderate traumatic brain injury in mice (73), insulin-like growth factor-2 treatment in APP transgenic mice (74), and intranasal insulin treatment of EcoHIV-infected mice (26). Since an HIV cure is still remote, mitigating NCI may be the only option to prevent deterioration of the disease with aging (3, 10).

MATERIALS AND METHODS

Mice. Male, 8-week-old 129X1/SvJ mice (Jackson Laboratory, Bar Harbor, ME) maintained under standard mouse husbandry conditions were used exclusively. Discomfort, distress, and injury to the animals were minimized. Animal studies were approved by the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC) in full compliance with the U.S. Animal Welfare Act and Public Health Service (PHS) policies and under Institutional PHS animal welfare assurance D16-00069.

Infectious virus stocks. The viruses used were EcoHIV/NDK (22), EcoHIV/NL4-3-GFP (27), and ecotropic MLV (75), referred to in the text as EcoHIV, EcoHIV-GFP, and MLV, respectively, as well as GFP-expressing MLV (MLV-GFP), kindly provided by Y. Sabo and S. Goff, Columbia University. Virus stocks were prepared, and titers were determined as described previously (23). MLV stocks were confirmed for infectivity in rat XC cells (76) and normalized for infection to EcoHIV stocks by shared envelope RNA content (23, 77).

Infection of mice, antiretroviral drug treatment, and tissue collection. Mice were infected by stereotaxic intracranial injection into the right hemisphere basal ganglia as previously described (24, 27) using 10⁶ pg of p24 of EcoHIV or virus RNA equivalents of MLV in 10 μl; the injection rate was 0.5 μl/min, and saline served as a control. Behavioral testing began 10 days postinfection. Antiretroviral (ARV) drugs were administered by gavage as a mixture of 100 mg/kg/day each of abacavir, indinavir, and raltegravir in water, starting 72 h before infection and twice daily until behavioral testing and then daily at 50 mg/kg/day until the end of behavioral testing. The gavage mixture was prepared from clinically available medications as described previously (23). Upon euthanasia, blood, spleens, and brains were removed and prepared for measurement of HIV burden, cellular gene expression, and microscopy as described previously (26, 27).

Mouse behavioral tests. Learning and memory were evaluated in groups of 8 to 10 mice using the radial arm water maze (RAWM) and auditory-cued fear conditioning (FC) tests as described previously (23, 26, 29). Briefly, RAWM testing consisted of four training trials (T), followed by a retention trial (RT) administered after a 30-min rest, repeated daily until control mice reached asymptotic performance of
one error or fewer on trials T4 and RT. Errors for the last 3 days of testing were averaged for statistical analysis. The hidden platform tests were followed by measuring the latency for finding a visible platform as a control for possible effects of treatment on animal vision, motivation, and motor ability. FC testing was conducted using an SDI Freeze Monitor (San Diego Instruments, San Diego, CA). Conditioning sessions included three consecutive pairings of 10-Hz sound signals and 0.7-mA electric shock signals; cued associative fear memory was measured the following day in a novel context by presenting sound signal alone. Results are shown as the mean total percentage of time spent freezing pre- and postcue on both the conditioning and the cued memory days.

**Measurement of virus burdens and cellular gene expression.** The procedures for harvesting mouse tissues, preparation of cellular DNA and RNA, and detection of EcoHIV/NDK gag transcript and 2LTR and gag DNA by real-time quantitative PCR (QPCR) were described previously (23, 78). QPCR detection of gp80 env RNA transcript and DNA common to EcoHIV and MLV by QPCR were as described previously (77), and detection of spliced nef transcripts by conventional RT-PCR and Southern blotting were as described previously (27). The spliced tat transcript was detected by RT-QPCR (79) with the following modifications: the reaction mixture contained custom-designed forward primer ND-tat-F (5′-CCT AGG ACT GCT TGT AAT AAG TGT-3′), reverse primer ND-tat-R2 (5′-GTC GGG TCC CCT CGG GAC GGG GAG-3′), and probe ND-tat-P (5′-(FAM)-AAA GGC TTA GGC ATC TC-(MGBNFQ)-3′). A standard curve for quantitation of tat copy number was constructed using graded numbers of plasmid TA-NDK-tat containing a spliced NDK tat cDNA fragment amplified with ND-tat-F and ND-tat-R2 primers and cloned into the TA-cloning pCR 2.1 vector (Thermo Fisher Scientific, Waltham, MA). Integrated EcoHIV/NDK proviral DNA was detected by a nested QPCR, as described previously (23). Samples for QPCR were run in duplicate in the AB7300 real-time thermal cycler (Thermo Fisher Scientific). RNA and DNA QPCR reactions were normalized by amplification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using a kit from ABI. Data were analyzed using the 7300 System software according to the manufacturer’s instructions. Changes in the expression of genes from mouse brain samples were analyzed by QPCR using TaqMan chemistry and probes from the Universal Probe Library (Roche, Indianapolis, IN), as previously described (27, 80). Relative quantification employed the comparative threshold cycle method (Applied Biosystems, technical bulletin 2).

**Histopathology, immunohistochemistry, and ELISA.** Mouse brains were fixed in 4% paraformaldehyde, dehydrated, embedded in paraffin, sectioned in 6-μm coronal sections, and either stained with H&E for histopathological assessment or used for the detection of HIV p24 and selected brain cell markers by immunohistochemistry, as described previously (27). The antibodies used were a rabbit polyclonal antibody to gial fibrillary acidic protein (GFAP) from Dako for labeling astrocytes; a rabbit polyclonal antibody to ionized calcium binding adaptor molecule-1 (Iba-1) from Wako (Osaka, Japan) for labeling macrophages/microglia, and a mouse monoclonal antibody 183-H12-SC (NIH AIDS Reagent Program, Germantown, MD; catalog no. 3537) for the detection of HIV-1 p24 antigen. Photomicrographs were taken on a Zeiss Photomicroscope III equipped with a Nikon DN100 digital camera. Quantification of immunostaining was performed using Volocity 5.5 image analysis software (Perkin-Elmer) on 10 to 20 images from multiple brain sections (five to eight images/section from two to three mice/group) and calculating the positive-stain area as a percentage of the total stained area per microscope field for each protein or counting stained cells or lesions per field normalized by image area. Two months after vehicle or EcoHIV injection, serum anti-HIV/NDK IgG was measured by an enzyme-linked immunosorbent assay (ELISA), as described previously (81).

**Immunofluorescence staining and confocal microscopy.** Mouse perfusion, preparation of frozen brain sections, immunofluorescence staining of sections, and confocal microscopy were performed as previously described (26, 27). The antibodies used were chicken anti-GFP (1:500; Thermo Fisher Scientific) for the detection of GFP in EcoHIV/NIL-4-GFP and MLV-GFP, rabbit anti-Ibα1 (1:400; Wako) to identify macrophages/microglia, rabbit anti-GFAP antibody (1:500; Thermo Fisher Scientific) to identify astrocytes, rabbit anti-microtubule-associated protein 2 (MAP2) for detection of dendrites (1:150; EMD Millipore, Mahopac, NY); rabbit anti-mouse synapsin II (Syn2) for detection of synapses (1:500; Abcam, Cambridge, MA), and mouse monoclonal anti-neuronal nuclear antigen (NeuN) for the detection of neuronal nuclei (1:150; EMD Millipore), followed by matching Alexa-conjugated secondary antibodies (1:100; Thermo Fisher Scientific). Images including Z-stacking were captured with a motorized Leica TCS SP5 confocal microscope and analyzed using Improvision Volocity software (Perkin-Elmer) as described previously (27). Quantification of images was performed using 10 to 20 images (two to four sections/mouse, three mice/group) measuring the intensity of staining for each protein in the selected areas indicated in Fig. 6C, as described previously (27).

**TUNEL assay for cellular apoptosis in mouse brain.** Cell death was determined on 6-μm paraffin-embedded brain sections using the TACS XL Blue Label kit ( Trevigen, Gaithersburg, MD), following the manufacturer’s protocol. For positive control, samples were treated with TACS-nuclease to generate DNA breaks in cells. Slides were examined under a Nikon light microscope and images were acquired by a Leica DFC425 camera. Image analysis was conducted by the LAS V4.0 program (Leica Microsystems, Inc., Buffalo Grove, IL) by counting the positively stained cells per mm² from 10 different fields from each of the three slide replicates for a total of 30 fields per group.

**Electrophysiology measurements in mouse hippocampus slices.** Extracellular field recordings were conducted using transverse hippocampal slices (400 μm) essentially as described previously (82, 83). Field extracellular postsynaptic potentials (fEPSPs) were recorded using a stimulating electrode at the Schaffer collateral fibers and a recording electrode at the CA1 stratum radiatum. Basal synaptic transmission was assessed by plotting stimulus voltages (V) against the corresponding fEPSP slopes. Stimulus intensity was set so that baseline responses were approximately 1/3 of the maximum response. Extracellular field recordings were conducted using transverse hippocampal slices (400 μm) essentially as described previously (82, 83). Field extracellular postsynaptic potentials (fEPSPs) were recorded using a stimulating electrode at the Schaffer collateral fibers and a recording electrode at the CA1 stratum radiatum. Basal synaptic transmission was assessed by plotting stimulus voltages (V) against the corresponding fEPSP slopes. Stimulus intensity was set so that baseline responses were approximately 1/3 of the maximum response.
evoked response. Long-term potentiation (LTP) was induced using theta-burst stimulation (four pulses at 100 Hz, with the bursts repeated at 5 Hz and each tetanus lasting 3 s) and separated by 15 s. Responses were measured as fEPSP slopes expressed as percentages of the baseline average.

**Statistical analysis.** Differences in HIV-1 burdens and other parameters between controls, infected, or treated mice were tested by unpaired Student t test with P values shown by asterisks in figures. RAWM data involving multiple comparisons were analyzed using a two-way analysis of variance (ANOVA) with a Holm-Sidak post hoc pairwise comparison. Individual trial data were analyzed using a one-way ANOVA with a Holm-Sidak post hoc pairwise comparison. Changes in cellular gene expression in the brain tissues of infected mice were first normalized to respective uninfected controls, with comparisons being made among each group. P value representations are indicated (*, P < 0.05; **, P < 0.01; ***, P < 0.001).

**ACKNOWLEDGMENTS**

This work was supported by grants R01DA037611 (D.J.V.), R01MH105145 (D.J.V.), R01NS094146 (M.J.P., D.J.V.), and NS049442 (O.A.) from the National Institutes of Health (NIH), Public Health Service. J.K. was in part supported by a Ruth L. Kirschstein National Research Service Award (5F32DA026311) from the NIH.

We thank Yosef Sabo and Stephen Goff, Columbia University, New York, for donating the MLV-GFP plasmid; Galina Bentsman for help in EcoHIV propagation, Eran Hadas for overseeing animal handling; and Ilene M. Totillo for help with manuscript preparation.

The authors declare no competing financial interests.

**REFERENCES**

1. Antonini A, Arendt G, Becker JT, Brew BJ, Byrd DA, Chermer N, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant J, Joseph J, Marder K, Marra CM, McCarthy JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. 2007. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789–1799. https://doi.org/10.1212/01.WNL.0000287431.88658.bb

2. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B. 2011. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 25:625–633. https://doi.org/10.1097/QAD.0b013e3283427da7

3. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfeison T, Gelman BB, McCutchan JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I. 2011. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:13–16. https://doi.org/10.1016/j.jnvr.2010.06.006-1

4. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. 2007. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915–1921. https://doi.org/10.1097/QAD.0b013e3282b28e2e27

5. Gates TM, Cysique LA. 2016. The chronicity of HIV infection should drive the research strategy of NeuroHIV treatment studies: a critical review. CNS Drugs 30:53–69. https://doi.org/10.1007/s10507-015-0302-7

6. Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC. 2016. HIV-associated neurocognitive disorder: pathogenesis and prospects for treatment. Nat Rev Neuro 12:234–248. https://doi.org/10.1038/nrneurol.2016.27

7. Grant I, Franklin DR, Jr, Deutsch R, Woods RP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McCutchan JC, Morgello S, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK, Group C. 2014. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 82:2055–2062. https://doi.org/10.1212/01.WNL.0000444892.000000

8. Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, Ragan A, Levine A, Miller E. 2016. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology 86:334–340. https://doi.org/10.1212/01.WNL.00004790012277

9. Bourlietle M-J, Yuen T, Fellows LK, Cysique LA, Heaton RK, Mayo NE. 2016. Identifying neurocognitive decline at 36 months among HIV-positive participants in the CHARTER Cohort using group-based trajec-
genesis of neurocognitive impairment in HIV. J Neurovirol 22:431–441. https://doi.org/10.1007/s11065-013-9510-7.

20. Gelman BB, Lisinichigia JG, Morgelio S, Maslieh E, Commins D, Achim CL, Fox HS, Kolon DL, Grant I, Singer E, Yannoutos CT, Sherman S, Gensler G, Moore DJ, Chen T, Soukup VM. 2013. Neurovirulological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr 62:487–495. https://doi.org/10.1097/QAI.0b013e31827f1dbd.

21. Dickens AM, Yoo SW, Chin AC, Xu J, Johnson TP, Trout AL, Hauser KF. 2014. Prefrontal cortical long-term potentiation. EMBO J 22:4121–4131.

22. Potash MJ, Chao W, Bentsman G, Paris N, Saini M, Nitekiewicz J, Belemen P, Sharer L, Brooks AV, Volksky DJ. 2005. A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A 102:3736–3740. https://doi.org/10.1073/pnas.0508649102.

23. Gu CJ, Borjabad A, Hadas E, Kelschenbach J, Kim BH, Chao W, Arancio O, Suh J, Polsky B, McMillan J, Edagwa B, Gendelman HE, Potash MJ, Volksky DJ. 2018. EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. PLoS Pathog 14:e1007061. https://doi.org/10.1371/journal.ppat.1007061.

24. Kelschenbach JL, Saini M, Hadas E, Gu C-J, Hanke T, Sharer L, Potash MJ, Volksky DJ. 2012. Mice chronically infected with chimeric HIV resist peripheral and brain superinfection: a model of protective immunity to HIV. J Neuroimmune Pharmacol 7:380–387. https://doi.org/10.1007/s11481-011-9316-1.

25. Nedelcovych MT, Tenora L, Kim B-H, Kelschenbach J, Chao W, Hadas E, Jančařík A, Prchalova E, Zimmermann SC, Dash RP, Gadano AJ, Garrett C, Furmtüller G, Oh B, Brandacher G, Alt J, Majer P, Volksky DJ, Rais R, Slusher BS. 2017. N-(Pivaloyloxy)alkoxy-carbonyl produgs of the glutamate antagonist 6-diazo-5-oxo-l-norleucine (DON) as a potential treatment for HIV associated neurocognitive disorders. J Med Chem 60:7186–7198. https://doi.org/10.1021/acs.jmedchem.7b00966.

26. Kim B-H, Kelschenbach J, Borjabad A, Hadas E, He H, Potash MJ, Nedelcovych MT, Rais R, Haughey NJ, McArthur JC, Slusher BS, Volksky DJ. 2019. Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders. AIDS 33:973–984. https://doi.org/10.1097/QAD.O00000000002150.

27. He H, Sharer LR, Chao W, Gu CJ, Borjabad A, Hadas E, Kelschenbach J, Ichyama K, Do M, Potash MJ, Volksky DJ. 2014. Enhanced human immunodeficiency virus type 1 expression and neuropathogenesis in knock-out mice lacking type I interferon responses. J Neuropathol Exp Neurol 73:59–71. https://doi.org/10.1097/NEN.0000000000000262.

28. Williams K, Burdo TH. 2012. Monocyte mobilization, activation markers, and acute neurocognitive symptoms in SIV-infected monkeys are informative with regard to pathogenic mechanisms of HIV infection in humans. J Neuroimmune Pharmacol 7:883–897. https://doi.org/10.1007/s13365-014-0346-y.

29. Ellis R, Langford D, Maloney J. 2007. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurol 8:33–44. https://doi.org/10.1038/nrneurol.2007.9.

30. Woods SP, Moore DJ, Weber E, Grant I. 2007. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 17:152–168. https://doi.org/10.1007/s11065-009-9102-5.

31. Kaul M, Zheng J, Okamoto S, Lipton SA. 2005. Cognitive function in older adults: a structural equation modeling approach. Neuropsychology 22:508–522. https://doi.org/10.1037/0894-4105.22.4.508.

32. Carroll A, Brew B. 2017. HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Res 6:312. https://doi.org/10.12688/f1000research.10651.1.

33. Ross JS, Suh J, Polsky B, McMillan J, Edagwa B, Gendelman HE, Potash MJ, Volsky DJ. 2014. Spatiotemporal profile of Map2 and microglial changes in the hippocampal CA1 region following pilocarpine-induced status epilepticus. Sci Rep. 6:24988. https://doi.org/10.1038/srep24988.

34. Cesca F, Baldelli P, Valtorta F, Benfenati F. 2010. The synapsins: key actors of synapse function and plasticity. Prog Neurobiol 91:313–348. https://doi.org/10.1016/j.pneurobio.2010.04.006.

35. Radza A, Teng J, Takyi Y, Oguchi K, Hirokawa N. 2002. MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. J Cell Biol 158:541–549. https://doi.org/10.1083/jcb.200110134.

36. Schartz ND, Herr SA, Madsen L, Butts SJ, Torres C, Mendez LB, Brewer DW. 2005. A mouse model for study of HIV-associated neurocognitive disorders. Neuropsychol Rev 19:152–168. https://doi.org/10.1023/B:NERV.0000000000001250.
selectivity of murine leukemia virus infection is determined by long
terminal repeat sequences. J Virol 55:862–866.
56. Sindberg GM, Sharma U, Banerjee S, Anand V, Dutta R, Gu CJ, Volsky DJ,
Roy S. 2015. An infectious murine model for studying the systemic
effects of opioids on early HIV pathogenesis in the gut. J Neuroimmune
Pharmacol 10:74–87. https://doi.org/10.1007/s11481-014-9574-9.
57. Douek D. 2007. HIV disease progression: immune activation, microbes,
and a leaky gut. Top HIV Med 15:114–117.
58. Klatt NR, Chomont N, Douek DC, Deeks SG. 2013. Immune activation
and HIV persistence: implications for curative approaches to HIV infection.
Immuno Rev 254:326–342. https://doi.org/10.1111/imr.12065.
59. Kovalevich J, Langford D. 2012. Neuronal toxicity in HIV CNS disease.
Future Virol 7:687–698. https://doi.org/10.2217/fvl.12.57.
60. Petito CK, Roberts B. 1995. Evidence of apoptotic cell death in HIV
encephalitis. Am J Pathol 146:1121–1130.
61. Petito CK, Roberts B, Cantando JD, Rabinstein A, Duncan R. 2001. Hip-
pocampal injury and alterations in neuronal chemokine coreceptor
expression in patients with AIDS. J Neuropathol Exp Neurol 60:377–385.
https://doi.org/10.1038/jnen.2017.63.
62. Epstein RA, Patai EZ, Julian JB, Spiers HJ. 2017. The cognitive map in
humans: spatial navigation and beyond. Nat Neurosci 20:1504–1513.
https://doi.org/10.1038/nn.4656.
63. Peterson J, Gisslén M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L,
Yannoutsos CT, Spudich SS, Price RW. 2014. Cerebrospinal fluid (CSF)
neuronal biomarkers across the spectrum of HIV infection: hierarchy of
injury and detection. PLoS One 9:e116081. https://doi.org/10.1371/journal.
pone.0116081.
64. Aden A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D,
Franklin D, Price RW, Grant I, Letendre SL, Gisslén M. 2016. Increased
intrathecal immune activation in virally infected HIV-1-infected pa-
tients with neurocognitive impairment. PLoS One 11:e0157160. https://
doi.org/10.1371/journal.pone.0157160.
65. Gelman BB, Endsley J, Kolson D. 2015. When do models of NeuroAIDS
faithfully imitate “the real thing”? J Neurovirol 24:146–155.
66. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young
1736–1739.
67. Franklin D, Price RW, Grant I, Letendre SL, Gisslén M. 2016. Increased
injury and detection. PLoS One 9:e116081. https://doi.org/10.1371/journal.
pone.0116081.
68. Kore I, Ananworanich J, Valcour V, Fletcher JLK, Chalermchai T, Paul R,
Flectow S, Ignatowska-Jankowska BM, Bull C, Skoff RP, Lichtman AH, Wise
LE, Fox MA, Su J, Medina AE, Krahe TE, Knapp PE, Guido W, Hauser KF.
2013. Synaptic dysfunction in the hippocampus accompanies learning
and memory deficits in human immunodeficiency virus type-1 Tat
transgenic mice. Biol Psychiatry 73:443–453. https://doi.org/10.1016/
jbip.sci.2012.09.026.
69. Benveniste EN, Shrikant P, Patton HK, Benos DJ. 1998. Neuroimmuno-
logic mechanisms for disease in AIDS: the role of the astrocyte. p
130–146. In Gendelman HE, Lipton AS, Epstein L, Swindells S (ed), The
neurology of AIDS. Chapman & Hall, New York, NY.
70. Clements JE, Babas T, Mankowski JL, Suryanarayana K, Piatak M, Jr,
Tanwar PM, Lifson JD, Zink MC. 2002. The central nervous system as a
reservoir for simian immunodeficiency virus (SIV): steady-state levels of
SIV DNA in brain from acute through asymptomatic infection. J Infect Dis
186:905–913. https://doi.org/10.1086/343768.
71. Huh JW, Raghu Pathi R, Lauer H, Helfmaer A, Saatman KE. 2003. Tran-
sient loss of microtubule-associated protein 2 immunoreactivity after
moderate brain injury in mice. J Neurotrauma 20:975–984. https://
doi.org/10.1089/neur.2011.0261.
72. Huh JW, Raghu Pathi R, Lauer H, Helfmaer A, Saatman KE. 2003. Tran-
sient loss of microtubule-associated protein 2 immunoreactivity after
moderate brain injury in mice. J Neurotrauma 20:975–984. https://
doi.org/10.1089/neur.2011.0261.
73. Pascual-Lucas M, Viana da Silva S, Di Scala M, Garcia-Barroso C, González-
Aseguinolaza G, Mulle C, Alberini CM, Cuadrado-Tejedor M, Garcia-Osta
A. 2014. Insulin-like growth factor 2 reverses memory and synaptic
deficits in APP transgenic mice. EMBO Mol Med 6:1246–1262. https://
doi.org/10.1002/emmm.201404228.
74. Gao G, Goff SP. 1998. Replication defect of Moloney murine leukemia
virus with a mutant reverse transcriptase that can incorporate ribonucleo-
tides and deoxyribonucleotides. J Virol 72:5906–5911.
75. Rowe WP, Pugh WE, Hartley JW. 1970. Plaque assay techniques for
murine leukemia viruses. Virolology 42:1136–1139. https://doi.org/10.
1016/0042-6822(70)90362-4.
76. Roy S. 2015. An infectious murine model for studying the systemic
response and a leaky gut. Top HIV Med 15:114–117.
77. Clements JE, Babas T, Mankowski JL, Suryanarayana K, Piatak M, Jr,
Tanwar PM, Lifson JD, Zink MC. 2002. The central nervous system as a
reservoir for simian immunodeficiency virus (SIV): steady-state levels of
SIV DNA in brain from acute through asymptomatic infection. J Infect Dis
186:905–913. https://doi.org/10.1086/343768.
78. Huh JW, Raghu Pathi R, Lauer H, Helfmaer A, Saatman KE. 2003. Tran-
sient loss of microtubule-associated protein 2 immunoreactivity after
moderate brain injury in mice. J Neurotrauma 20:975–984. https://
doi.org/10.1089/neur.2011.0261.
79. Saini M, Hadas E, Volsky DJ, Potash MJ. 2007. Vaccine-induced protection
from infection of mice by chimeric human immunodeficiency virus type
1, EcoHIV/NL4-3. Vaccine 25:8660–8663. https://doi.org/10.1016/j.
vaccine.2007.10.019.
80. Hadas E, Borjabad A, Chao W, Saini M, Ichiyama K, Potash MJ, Volsky
D. 2007. Testing antiretroviral drug efficacy in conventional mice infected
with chimeric HIV-1. AIDS 21:905–909. https://doi.org/10.1097/QAD.
0b013e3281574549.
81. Sirois M, Robitaille L, Allary R, Shah M, Woelk CH, Etstajjer Q, Corbeil J.
2011. TRAF6 and IF7 control HIV replication in macrophages. PLoS One
6:e28125. https://doi.org/10.1371/journal.pone.0028125.
82. Borjabad A, Morgello S, Chao W, Kim S-Y, Brooks AI, Murray J, Potash MJ,
Volsky DJ. 2011. Significant effects of antiretroviral therapy on global
gene expression in brain tissues of patients with HIV-1-associated neu-
rocognitive disorders. PLoS Pathog 7:e1002213. https://doi.org/10.1371/
journal.ppat.1002213.
83. Hadas E, Chao W, He H, Saini M, Daley E, Safiuddin M, Bentsman G, Ganz
E, Volsky DJ, Potash MJ. 2013. Transmission of chimeric HIV by mating in
conventional mice: prevention by pre-exposure antiretroviral therapy and
reduced susceptibility during estrus. Dis Model Mech 6:1292–1298.
https://doi.org/10.1242/dmm.012617.
84. Lee L, Dale E, Staniszweski A, Zhang H, Saeed F, Sakurai M, Fà M, Orozco
I, Michelassi F, Akpan N, Lehrer H, Arancio O. 2014. Regulation of synaptic
plasticity and cognition by SUMO in normal physiology and Alzheimer’s
disease. Sci Rep 4:7190.
85. Puzzo D, Privitera L, Lenzik E, Fà M, Staniszweski A, Palmeri A, Arancio O.
2008. Picomolar amyloid-b positively modulates synaptic plasticity and
memory in hippocampus. J Neurosci 28:14537–14545. https://doi.org/10.
1523/JNEUROSCI.2692-08.2008.